Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Details
Commercially available molecular tests for human papillomaviruses : a global overview
ID
Poljak, Mario
(
Author
),
ID
Oštrbenk Valenčak, Anja
(
Author
),
ID
Gimpelj Domjanič, G.
(
Author
),
ID
Xu, Lan
(
Author
),
ID
Arbyn, Marc
(
Author
)
PDF - Presentation file,
Download
(901,18 KB)
MD5: 563C56923FAA3F6C750C970B7B8C478E
URL - Source URL, Visit
https://www.sciencedirect.com/science/article/pii/S1198743X20301798
Image galllery
Abstract
Background: Molecular tests for detection of human papillomaviruses (HPVs) play a crucial role in the prevention of cervical cancer, including recently announced elimination efforts. HPV testing is a recommended approach for cervical cancer screening of women over 30 and for management of those with precancerous cervical lesions. In addition, they are widely used in epidemiological studies, HPV surveillance and vaccination impact monitoring. Objectives: The aim was to provide an updated 2020 inventory of commercial molecular HPV tests available on the market. Sources: Data were retrieved from internal files, and a detailed search using Medline/Pubmed, Web of Science, Scopus, Google Scholar, Google and Bing, without language or period restrictions, was performed in September 2019 and again in January 2020. Content: We identified 254 distinct commercial HPV tests and at least 425 test variants available on the global market in 2020, which represents a 31% and 235% increase in the number of distinct tests and variants, respectively, compared with the previous inventory performed in 2015. Although the proportion of commercially available HPV tests with at least one peer-reviewed publication has increased over the past decade, 60% of the HPV tests on the global market are still without a single peer-reviewed publication. Furthermore, 82% of tests lack any published analytical and/or clinical evaluation, and over 90% are not evaluated in line with consensus requirements that ensure safe use in clinical settings. Implications: Significant challenges and scope for improvement still exist for both the HPV scientific community and the manufacturers of HPV tests. The latter must put more effort into validating their products, in agreement with standardized procedures, including all steps of HPV testing and various clinical specimens. High throughput capacity and point-of-care HPV tests are needed, both with affordable prices.
Language:
English
Keywords:
cervical cancer
,
human papillomaviruses
,
commercial tests
,
HPV
,
screening
Work type:
Article
Typology:
1.02 - Review Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2020
Number of pages:
Str. 1144-1150
Numbering:
Vol. 26, iss. 9
PID:
20.500.12556/RUL-137785
UDC:
618.1
ISSN on article:
1198-743X
DOI:
10.1016/j.cmi.2020.03.033
COBISS.SI-ID:
27596547
Publication date in RUL:
30.06.2022
Views:
1281
Downloads:
176
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Clinical microbiology and infection
Publisher:
Elsevier, European Society of Clinical Microbiology and Infectious Diseases
ISSN:
1198-743X
COBISS.SI-ID:
71154
Licences
License:
CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:
http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:
The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Secondary language
Language:
Slovenian
Keywords:
rak materničnega vratu
,
človeški papiloma virusi
,
komercialni testi
Projects
Funder:
EC - European Commission
Funding programme:
FP7
Project number:
603019
Name:
Comparing health services interventions for the prevention of HPV-related cancer
Acronym:
COHEAHR
Funder:
EC - European Commission
Funding programme:
H2020
Project number:
847845
Name:
Risk-based screening for cervical cancer
Acronym:
RISCC
Funder:
ARRS - Slovenian Research Agency
Project number:
P3-0083
Name:
Odnosi parazitskega obstajanja
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back